The stock has experienced significant weakness over the past six months, declining 15.46% from October 2025 levels. This downtrend accelerated in the last three months, with the price falling 18.17%, underperforming the broader market significantly as indicated by a -13.54% relative strength. The stock is currently trading at $242.39, which is near the lower end of its 52-week range of $214.50 to $324.90, representing a drawdown of approximately 29.09% from its high. While the stock showed a modest gain of 0.91% over the past month, this short-term bounce has not reversed the dominant bearish trend established since late 2025.

Revenue in Q4 2025 was $19.69 billion, showing a 12.15% year-over-year growth from the prior-year quarter. Profitability has improved significantly, with the net income margin reaching 28.45% in Q4 2025, a substantial recovery from the -2.20% margin in Q3 2024. The company's financial health shows a high degree of leverage, with a debt-to-equity ratio of 2.06, but it maintains a strong trailing twelve-month free cash flow of $12.28 billion. Operational efficiency is robust, with a return on equity (ROE) of 32.45% and a return on assets (ROA) of 5.44% as of the latest data, indicating effective use of capital.